The interleukin (IL)-1 family of cytokines is currently comprised of 11 members that have pleiotropic functions in inflammation and cancer. IL-1α and IL-1β were the first members of the IL-1 family to be described, and both signal via the same receptor, IL-1R. Over the last decade, much progress has been made in our understanding of biogenesis of IL-1β and its functions in human diseases. Studies from our laboratory and others have highlighted the critical role of nod-like receptors (NLRs) and multi-protein complexes known as inflammasomes in the regulation of IL-1β maturation. Recent studies have increased our appreciation of the role played by IL-1α in inflammatory diseases and cancer. However, the mechanisms that regulate the production of IL-1α and its bioavailability are relatively understudied. In this review, we summarize the distinctive roles played by IL-1α in inflammatory diseases and cancer. We also discuss our current knowledge about the mechanisms that control IL-1α biogenesis and activity, and the major unanswered questions in its biology.
| IL-CYTOKINE AND RECEPTOR FAMILY
Interleukins were first identified as pyrogenic molecules produced by leukocytes incubated with lipopolysaccharide (LPS) that also enhance the T cell response to lectins.
1,2 Dinarello et al, identified two distinct pyrogens produced by monocytes and neutrophils upon stimulation with heat-killed Staphylococcus. 3, 4 With the advent of DNA sequencing strategies, these pyrogenic molecules were later described as IL-1α and IL-1β. 5 The IL-1 family is now comprised of 11 members (IL-1α, IL-1β, IL-18, IL-33, IL-36α, IL-36β, IL-36γ, IL-1R antagonist (IL-1Ra), IL-36Ra, IL-37, and IL-38) which can have complimentary or distinct biological functions. 6 Most of the genes encoding the members of the IL-1 cytokine family are located on human chromosome 2, except for IL-18 and IL-33 encoding genes that are located on chromosomes 11 and 9, respectively. Cytokines of the IL-1 family share a common structure at the C-terminus, which is comprised by of a typical β-trefoil fold consisting of 12-β-strands connected by 11 loops. 7 While IL-1 receptor antagonist (IL-1Ra) possesses a leader secretion sequence that targets it for secretion via the endoplasmic reticulum (ER)-golgi pathway, all other IL-1 cytokines require unconventional pathways of maturation and/or release from the cell. IL-1α, IL-33, and IL-36 possess a nuclear localization signal and localize to the nucleus under homeostatic conditions. However, the function of nuclear localization of these cytokines is unclear. IL-1β and IL-18 are expressed as inactive zymogens that are activated by cleavage in the N-terminal region by caspase-1, which is itself activated by formation of a multi-protein complex known as the inflammasome. 8, 9 The release of other IL-1 cytokines in bioactive forms is also thought to require some form of inflammatory cell death. 10 Therefore, the activity of IL-1 cytokines is tightly regulated not only at the level of expression, but also maturation by activated caspases and release from the cell by cell death pathways.
Binding of the cognate IL-1 agonist to the specific receptor leads to the recruitment of the co-receptor, followed by activation of intracellular signaling. Receptors of the IL-1 cytokines typically possess three immunoglobulin (Ig) domains and one Toll-like/IL-1R (TIR) domain.
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Signaling downstream of the receptors can be further modulated by membrane-bound and soluble decoy receptors, accessory proteins, and antagonists. The IL-1 receptor family is comprised of several members including IL-1R1 (commonly referred to as IL-1R), decoy receptor IL-1R2, IL-1R accessory protein (IL-1RaP or IL-1R3), IL-1R4 (T1 or ST2),
IL-18Rα (IL-1R5), IL-36R (IL-1R6), IL-18R accessory protein (IL-18Rβ or IL-1R7), IL-1R8 (TIR8), IL-1R9 (IL-1RAPL2), and IL-1R10 (TIGIRR)
. 11, 12 IL-1α and IL-1β are agonists of IL-1R, whereas IL-18 and IL-36 bind to IL-18Rα and IL-36R, respectively, to induce activation of downstream signaling in a MyD88-dependent manner. IL-1R1, IL-1R2, IL-1R4, and IL-36R share the co-receptor IL-1RaP, whereas IL-18Rα utilizes IL-18Rβ
as the accessory receptor. 12 The decoy receptors are unable to initiate a signaling cascade as they lack the cytoplasmic TIR domains. IL-1Ra
and IL-36Ra are soluble receptor antagonists that preclude activation of the cognate receptors. 11, 12 Furthermore, a secretory form of IL-1R1
(sIL-1R1) also inhibits IL-1α, IL-1β, and IL-1Ra. 13 Both IL-1α and IL-1β are translated into 31 kDa pro-forms. However, unlike pro-IL-1β, pro-IL-1α has a functional nuclear localization signal (NLS) in the N-terminal domain. 30, 31 In epithelial cells, myeloid cells, and keratinocytes, pro-IL-1α is shuttled to the nucleus upon translation. In contrast, in vascular smooth muscle cells, NLS of pro-IL-1α is masked by interaction with intracellular form of IL-1R2 that leads to its cytosolic retention. 32 The mechanisms that regulate sub-cellular targeting of IL-1α in different cell types and under different stimulation conditions are largely unknown. HS-1-associated protein X (HAX)-1 is a protein associated with mitochondrial, endoplasmic reticulum, and the nuclear membranes, and can bind to pro-IL-1α and promote its nuclear localization. 33, 34 Using overexpression systems, pro-IL-1α
has been suggested to interact with histone acetyltransferases p300, P300/CBP-associated factor (PCAF) and GCN5 in the nucleus 35, 36 and modulate gene expression independently of IL-1R. 37, 38 Furthermore, pro-IL-1α is post-transnationally modified, including myristoylation or acetylation on Lys82 39, 40 and phosphorylation at Ser90. 41, 42 The functions of these modifications are also largely unknown (Figure 1 ).
Like pro-IL-1β, pro-IL-1α is also cleaved by proteases, including caspase-1, to yield the bioactive 17 kDa form and the 16 kDa Nterminal cleavage product termed as the pro-piece. 43 Pro-IL-1α can also be cleaved by calpain, chymase, elastase, and granzyme B in the intracellular or extracellular space to yield mature IL-1α. [44] [45] [46] [47] While cleavage of pro-IL-1β by caspase-1 is required to generate bioactive IL-1β, both pro-IL-1α and mature IL-1α bind to IL-1R with similar kinetics 48 and have similar biological activity on epithelial and hematopoietic cells, as judged by their ability to induce secretion of IL-6
and TNF. 49 Therefore, the biological role of proteolytic processing of IL-1α is currently unknown. Caspase-1 activation by inflammasomes does, however, facilitate secretion of IL-1α (and other inflammasomeassociated cytokines) by inducing an inflammatory form of cell death termed as pyroptosis. 43, 50 In addition to the cytokines (IL-1 and IL-18), active caspase-1 also cleaves the cell death executioner, Gasdermin D (GSDMD). [51] [52] [53] [54] Upon cleavage, the N-terminal fragment of GSDMD oligomerizes and inserts into the cell membrane, leading to loss of osmotic potential, cell swelling and eventual bursting that is accompanied by release of cytoplasmic contents, including IL-1α and IL-1β, from the cell. 51, 52, [54] [55] [56] [57] [58] [59] [60] Therefore, inflammasome activation and subsequent pyroptosis is a mechanism of release of IL-1α from the cell, even though the processing of IL-1α by caspase-1 is dispensable for its bioactivity.
As they signal via the same receptor, release of IL-1α alongside IL-1β during inflammasome activation may supplement IL-1R activation by IL-1β. In certain cell types, binding of cytosolic IL-1R2 holds pro-IL-1α
in an inactive state, as the pro-IL-1α-IL1R2 complex that is released upon necrotic death cannot signal via IL-1R. 32 This inhibition of IL-1α activity by IL-1R2 can be relieved by active caspase-1, as it can cleave IL-1R2, which leads to its dissociation from pro-IL-1α. 32 Therefore, inflammasome activation may indirectly promote IL-1α bioavailability by relieving IL-1R2 inhibition. However, proof of such inhibition of IL-1α, or the requirement of inflammasomes for its bioactivity has not been confirmed under in vivo settings.
A membrane-associated form of the full-length pro-IL-1α has also been observed. Exposure of innate immune cells or endothelial cells to inflammatory stimuli such as LPS or heat-killed Mycobacterium tuberculosis leads to upregulation of IL-1α expression, and pro-IL-1α can be detected in the cytoplasm, the nucleus, and the plasma membrane. [61] [62] [63] This membrane-associated form of pro-IL-1α is also bioactive, as it can signal via IL-1R in a paracrine manner to promote T cell proliferation and chemokine secretion. [64] [65] [66] [67] This membrane-association property of IL-1α is unique in the IL-1 family, and simultaneous localization in the nucleus, cytoplasm, and the plasma membrane is unique among all known cytokines. Membrane-bound pro-IL-1α is glycosylated 66 suggesting the involvement of a lectin in its membrane targeting or localization. Plasma-membrane-bound pro-IL-1α can also be cleaved by extracellular proteases to yield the mature form of IL-1α, or cause its inactivation. 47, 67, 68 The mechanisms that regulate the cytosolic, cellular membrane, or nuclear trafficking of IL-1α, and their relative functions are major questions in the biology of IL-1α. In recent years, IL-1α has also emerged as an apical driver of cutaneous inflammation, [115] [116] [117] colon inflammation and cancer, 118 cardiovascular disease, 23 and neural inflammation. 119 We have shown that IL-1α has a non-redundant role in driving autoinflammatory disease in a mouse model of neutrophilic dermatoses. 117 Neutrophilic dermatoses are a heterogeneous group of autoinflammatory skin disorders that are associated with cutaneous inflammatory lesions and include Sweet's syndrome, pyoderma gangrenosum, subcorneal pustular dermatosis, and hidradenitis suppurativa. [120] [121] [122] Our studies show that IL-1α has a non-redundant role in driving SHP1-mediated neutrophilic dermatoses as genetic ablation of IL-1α, but not IL-1β protects the Ptpn6 spin mice from disease development. 117 Transgenic mice that overexpress IL-1α in epidermal cells also develop an inflammatory skin disease, underscoring the pathogenic role of excess IL-1α production in skin inflammation. 133 Bone marrow chimera studies further reveal that while Ptpn6 spin mutation in hematopoietic cells is required for disease development in these mice, the non-hematopoietic cells are the primary source of pathogenic IL-1α. 134 Microabrasion injury in the footpads also accelerates disease progression and enhances severity in prediseased Ptpn6 spin mice, suggesting that passive release of IL-1α from epidermal cells during necrotic cell death is an instigator of disease. 117 Microabrasion in the footpads of WT mice also leads to enhanced TNF-α, G-CSF, and KC production in an IL-1α-dependent manner. 134 However, production of IL-1α, as well as G-CSF and KC is unaffected in the microabrated footpads of TNF-α-deficient mice. 134 Furthermore, genetic deletion of TNF-α or TNFR adaptor tumor necrosis factor receptor type 1-associated death domain protein (TRADD) in Ptpn6 spin mice only partially protects mice from the disease. 134 Taken together, these data show that IL-1α is the apical cytokine that induces production of other pro-inflammatory cytokines and ultimately recruits neutrophils to drive the autoinflammatory disease in Ptpn6 spin mice.
| IL-1α AS AN APICAL INSTIGATOR OF INFLAMMATION
Unlike CAPS and FMF, the IL-1-driven cutaneous inflammation in 134 These studies demonstrate that IL-1α production from non-hematopoietic cells and scaffolding activity of RIPK1 is required for disease development in Ptpn6 spin mice, whereas RIPK3
and MLKL-mediated necroptosis is dispensable. Ubiquitination of RIPK1 allows it to act as a scaffold to support transforming growth factor-β activated kinase 1 (TAK1) recruitment to the RIPK1 complex, which is central to signaling events downstream of both IL-1R
and TLRs. 142, 143 Our recent study shows that scaffolding activity of RIPK1 coordinates with TAK1 to provoke disease. 134 We also show that SHP-1 controls activation of spleen tyrosine kinase (SYK), which further regulates MyD88 phosphorylation in myeloid cells. 144 Consequently, Ptpn6 spin mice that are also deficient in TAK1 or SYK in myeloid cells are also protected from disease development. Overall, studies from the Ptpn6 spin mice demonstrate that IL-1α production from non-hematopoietic cells acts on myeloid cells in a SYK, MyD88, RIPK1, and TAK1-dependent manner, and this pathway is negatively regulated by SHP-1 to restrain excessive IL-1R signaling and associated autoinflammation (Figure 2 ). apical driver of SSc, knock-down of IL-1α also reduced the proliferation, and levels of secreted IL-6, PDGF-α, and pro-collagen in SSc-associated fibroblasts. On the other hand, levels of IL-6, PDGF-α, and collagen are increased in normal fibroblasts when pro-IL-1α is over-expressed. 149, 150 IL-1α has also been suggested to be a sensor of genotoxic stress. 40 Upon induction of DNA-damage by exposure to UV or genotoxic agents, IL-1α co-localizes with gH2AX and HDAC-1 at the sites of DNA-damage.
While the function of IL-1α nuclear localization is not known, acetylation of IL-1α within the NLS is required for this nuclear localization.
Furthermore, secretion of IL-1α from the skin lesions, via unknown mechanisms, drives neutrophil infiltration in the affected tissue. 40 IL-1α is also associated with driving inflammation at mucosal barrier surfaces. IL-1α, but not IL-1β-deficient mice are protected from acute colitis induced by oral feeding of cytotoxic agent dextran sodium sulfate (DSS). 118, 152 Furthermore, epithelial cells are the primary source of this pathogenic IL-1α. 118 We also demonstrated that another member of the IL-1 cytokine family, IL-33, promotes IgA production in the intestine, which in turn supports symbiotic gut microbiota. 152 Consequently, IL-33-deficient mice have a dysbiotic microbiota characterized by increased levels of mucolytic and colitogenic bacteria. 
| IL-1α AND MICROBIAL DISEASES
Consistent with its role as an alarmin, IL-1α also plays a nonredundant role in instigating host defense against multiple infectious agents. Exposure to Mycobacterium tuberculosis leads to upregulation of IL-1α and IL-1β expression in macrophages and epithelial cells. 156 IL-1 signaling cooperates with TNF signaling to promote granuloma formation, which help sequester the bacteria. The absence of IL-1α, IL-1R, or TNFR in the host leads to failure of granuloma formation, and increased mortality in the host. 63, 156 The synergy between IL-1α and TNF signaling is also protective from gut-derived sepsis induced by Pseudomonas aeruginosa colonization and cyclophosphamide induced immune-suppression. 157 
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IL-1α is also the initiator of neutrophil influx in the lungs following infection with an intracellular bacterial pathogen Legionella pneumophila, the cause of severe pneumonia called Legionnaires' disease. 166 IL-1α production in hematopoietic cells is necessary for neutrophil infiltration following L. pneumophila infection, whereas IL-1β has a relatively minor role. Furthermore, while inflammasome activation is necessary for IL-1β secretion, it is dispensable for IL-1α release following L. pneumophila infection. 166 IL-1 also exacerbates neutrophilia in response to Haemophilus influenzae infection and cigarette smoke exposure, in a CXCR2-dependent manner. 167 Specific IL-1α blockade also restricts intestinal inflammation induced by Yersinia enterocolitica 168 or cytotoxic agent DSS. 152 In contrast, exogenous administration of IL-1α
ameliorates intestinal ischemia and reperfusion injury by reducing intestinal permeability and bacterial translocation during thermal injury and endotoxemia. 169 The mechanisms that control the bioavailability of IL-1α following these infections or treatments are not known. It is also unknown if specific sub-cellular localization, post-translational modification or proteolytic processing of IL-1α is required for these functions.
IL-1α also plays a role in neutrophil recruitment and host de- IL-1α expression also precedes IL-1β expression in the brain after systemic infection with the fungal pathogen Cryptococcus neoformans 173 and supports neutrophil recruitment in the lung following Apsergillus fumigatus infection. 174 IL-1α induced neutrophil recruitment can also be a driving factor for tissue damage during infections. In the genetically susceptible BALB/c mice, protozoan parasite Leishmania major induces pathology in an IL-1α-dependent manner. 175 However, transient local administration of IL-1α during cutaneous leishmaniasis promotes IFN-γ production from T cells, which is protective for the host. 176 IL-1α also drives neutrophil infiltration in lungs during RSV infection, in an IL-1R-dependent manner. 177 Therefore, IL-1α can drive immunopathology or protective immune responses during infections, and IL-1α activity must be tightly controlled to protect from destructive inflammation while also boosting anti-microbial immunity. factor (VEGF) in the tumor tissue. [194] [195] [196] 3-Methylcholanthrene (MCA) induced fibrosarcoma development requires IL-1β, but not IL-1α expression in the host. 197 However, IL-1α expression in the 3-MCA-induced fibrosarcoma cell line is required for tumor development upon implantation in a naïve host. 198 constitutively secrete mature IL-1β via the canonical ER-golgi secretion pathway. 188, 199 Upon implantation into a naïve host, these tumor cells demonstrate increased growth, angiogenesis, and invasiveness. 188, [199] [200] [201] [202] Furthermore, both IL-1β and VEGF synergize to promote angiogenesis in the tumors. 203 Increased IL-1α production is associated with distant metastases, and poor survival rate in head and neck squamous cell carcinoma and gastric carcinoma. 204, 205 IL-1α
| IL-1α AND CANCER
is also a major driver of colon cancer that is associated with chronic inflammation in the colon. 152 A single-nucleotide polymorphism (SNP) in the IL1a gene that leads to A114S substitution is associated with increased risk of ovarian cancer. 206 The A114S mutant form of pro-IL-1α form is more readily cleaved by inflammatory proteases, underscoring the idea of increased IL-1 secretion leading to increased tumorigenicity and metastasis. 207 In contrast with these observations, overexpression of cytosolic or membrane-bound forms of IL-1α leads to the regression of fibrosarcoma. 208, 209 The protection conferred by overexpression of IL-1α is associated with enhanced immune-surveillance mechanisms that depend on CD8 + T cells, NK cells, and M1-differentiated macrophages. 210 ,211 IL-1α-mediated anti-tumor immune response also leads to development of immunological memory that is protective from re-challenge with parental tumor cells. 210, 211 Similarly, IL-1β (and IL-18) maturation by the NLRP3 inflammasome activated by chemotherapeutic drugs contributes toward activation of anti-tumor CD8 + T cells. 193 However, it was suggested that chemotherapy-enhanced production of pro-inflammatory mediators potentiate tumor invasiveness and metastasis. 212, 213 Taken together, these studies suggest that while IL-1 signaling is inherently pro-tumorigenic, focused, local stimulation provided by membrane-bound or low levels of secreted of IL-1 can be beneficial by boosting anti-tumor immunity.
Clinical trials with an IL-1α-blocking monoclonal antibody have shown promising outcomes in patients with end-stage cancers. 144, 214 MABp1 (XBiotech Inc.) is a naturally occurring human interleukin-1α neutralizing antibody. Monotherapy with MABp1 improved survival rate, increased lean body weight, normalized paraneoplastic thrombocytosis, decreased levels of serum IL-6 and associated systemic inflammation and cachexia without significant side-effects in patients with advanced non-small cell lung cancer, ovarian cancer, and other refractory cancers. 144, [215] [216] [217] MABp1 treatment also improved clinical parameters in patients with unresectable or metastatic colon cancer. 218 Therefore, it is clear that IL-1α is a clinically significant driver of cancer and associated complications. Further clinical trials with these and other types of cancers, and in earlier stages of the disease, are warranted.
Senescence-associated secretory phenotype (SASP) is a phenomenon characterized by spontaneous production of low levels IL-6, IL-8, and other inflammatory mediators by aged cells undergoing senescence. 219 Sustained production of inflammatory mediators at low levels leads to chronic systemic inflammation. This low-level chronic inflammation has been associated with age-related pathologies and cancer as IL-6 and other inflammatory mediators promote angiogenesis and proliferation of malignant cells. 219 IL-1α expression after exposure to ionizing radiation enhances SASP, and inhibition of mTOR by rapamycin treatment represses IL-1α translation, resulting in suppression of SASP. 219, 220 Initial IL-1α production results in amplification of production of pro-inflammatory and pro-tumorigenic factors, and consequently SASP in fibroblasts and epithelial cells is associated with worsening prognosis for cancer. 190 Therefore, similar to autoinflammatory disorders and infections, IL-1α can also be an apical driver of SASP.
| CONCLUSIONS AND FUTURE PERSPECTIVES
New studies propose a paradigm of IL-1α-dependent pro- Mechanisms that regulate IL-1α secretion from the cell, and the function of its cleavage by inflammatory proteases are also unknown. Due to its ubiquitous expression, potent activity and bioavailability, IL-1α has emerged as a major player and drug target in many diseases. Further understanding of the regulation IL-1α will undoubtedly help develop novel therapeutics for the vast array of ailments associated with this cytokine.
